BioLife Solutions (NASDAQ:BLFS) Major Shareholder Casdin Partners Master Fund, L Sells 250,000 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) major shareholder Casdin Partners Master Fund, L sold 250,000 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $23.70, for a total transaction of $5,925,000.00. Following the transaction, the insider owned 5,407,165 shares of the company’s stock, valued at $128,149,810.50. This trade represents a 4.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Casdin Partners Master Fund, L also recently made the following trade(s):

• On Thursday, May 21st, Casdin Partners Master Fund, L sold 650,000 shares of BioLife Solutions stock. The stock was sold at an average price of $23.70, for a total transaction of $15,405,000.00.
• On Tuesday, May 19th, Casdin Partners Master Fund, L sold 300,000 shares of BioLife Solutions stock. The stock was sold at an average price of $22.65, for a total transaction of $6,795,000.00.

BioLife Solutions Stock Performance

Shares of NASDAQ:BLFS opened at $24.74 on Friday. The company has a fifty day moving average of $20.58 and a 200-day moving average of $22.94. The company has a market capitalization of $1.21 billion, a PE ratio of -309.21 and a beta of 1.97. BioLife Solutions, Inc. has a 52-week low of $17.86 and a 52-week high of $29.62.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.03. The company had revenue of $27.50 million during the quarter, compared to the consensus estimate of $25.66 million. BioLife Solutions had a negative net margin of 2.80% and a positive return on equity of 1.81%. On average, equities analysts forecast that BioLife Solutions, Inc. will post 0.09 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on BLFS. Wall Street Zen upgraded shares of BioLife Solutions from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Zacks Research downgraded shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a research note on Monday, April 20th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $32.00.

Hedge Funds Weigh In On BioLife Solutions

Several large investors have recently modified their holdings of BLFS. Jacobs Levy Equity Management Inc. bought a new position in shares of BioLife Solutions during the first quarter valued at $283,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of BioLife Solutions by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,422 shares of the medical equipment provider’s stock valued at $489,000 after acquiring an additional 914 shares during the last quarter. Jane Street Group LLC bought a new position in shares of BioLife Solutions during the first quarter valued at $1,091,000. Strs Ohio bought a new position in shares of BioLife Solutions during the first quarter valued at $153,000. Finally, Qube Research & Technologies Ltd raised its stake in shares of BioLife Solutions by 2,399.5% during the second quarter. Qube Research & Technologies Ltd now owns 248,474 shares of the medical equipment provider’s stock valued at $5,352,000 after acquiring an additional 238,533 shares during the last quarter. Institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.